{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

test3251235 - America according to a study done by Michael...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
CURRENT RESEARCH A. HISTORY OF THE DESEASE This rare desease was first observed in 1859 by the Frech doctor Pierre Landry, which described a simple neuropathy in one of his patients (Amato). Posteriorly, in 1916 the desease was studied to a greater extent by three French scientists, Guillain, Barre and Strohl. They observed, amongst other symptoms, a noticeable degree of areflexia in the patient’s skeletal muscles which appeared to be progressive over the following days (Amato). Today, the Guillain-Barre Syndrome (GBS) according to the Japanese Neurologist Satoshi Kuwabara, can be best described as an “acute peripheral neuropathy” which includes a progressive degenerative process over a period of time that varies from a couple of days up to a month. The median annual incidence for GBS in the world is about 1.3 in hospital proved cases in a population of 100’000 (Kwabara). In North
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: America, according to a study done by Michael Rubin (Professor of Clinical Neurology at the Weill Cornell Medical College in New York) and the Agency for Healthcare Research and Quality (from the US department of Human and Health Services) the GBS incidence rate was about 1.65 per population of 100’000. B. SYMPTOMS AND CAUSES Most of the analyzed journals concur in two chief aspects: Firstly, there are several subtypes of GBS and furthermore, the term Acute Inflammatory Demyelinating Polineuropathy (AIDP for short), can be used as a synonym for GBS (Kwabara). A patients with GBS present paresthesia (tingling sensation in skin) and numbness (Amato), but the major symptom is progressive muscular weakness which, according to … is symmetric....
View Full Document

{[ snackBarMessage ]}